AI-Powered Precision for Risk of Recurrence Prediction
Ataraxis™ Breast RISK
Ataraxis Breast RISK is an AI-powered test that provides personalized recurrence risk prediction for stage I–III breast cancer patients. By analyzing morphological features from standard H&E slides together with clinical data, the test delivers both a precise risk estimate to help personalize care.
Introducing next-generation technology for prediction of breast cancer recurrence
Building on tens of thousands of real-world and clinical trial cases, Ataraxis Breast RISK helps resolve uncertainty in challenging and inconclusive cases, such as patients considered to be intermediate risk or borderline by standard clinical characteristics and genomic tests.
Ataraxis Breast RISK was developed and validated using data from all early-stage breast cancer patients, including HR+/HER2-, but also triple-negative (TNBC), HER2-positive, and triple-positive breast cancer.
Ataraxis Breast RISK was found to provide independently prognostic information, unique from standard clinicopathological features and genomic assays.
How do we predict risk of recurrence?
Development & Clinical Validation
Robust development and validation data
Ataraxis Breast RISK was developed and validated using data from 8,161breast cancer patients treated at 15 institutions in 7 countries.
The study included patients with all subtypes of early-stage and locally advanced invasive breast cancer, marking this as one of the most comprehensive evaluations of a prognostic/predictive test.
Over 50% improvement in accuracy compared to standard of care genomic tests
In validation of the Ataraxis Breast RISK score on three external cohorts from top international cancer centers, Ataraxis Breast reduced prediction error by approximately 50% compared to the standard of care genomic assays for hormone receptor-positive invasive breast cancer.
Works in all clinically relevant invasive breast cancer subgroups
Ataraxis Breast RISK was developed and validated on robust and diverse data from seven countries. The data included previously underserved groups, such as triple-negative breast cancer patients. Ataraxis Breast RISK was shown to be consistently prognostic across groups with various age, race, molecular and histological subtype, and nodal status.
Superior calibration to real-world outcomes
Traditional prognostic tools, including widely used genomic assays, often provide relative risk scores. These scores indicate who is higher or lower risk within a population, but they do not reliably match the true recurrence probabilities patients experience in practice.
Ataraxis Breast RISK is fundamentally different. It is designed not only to rank patients by risk, but to produce absolute risk estimates that reflect what actually happens in real-world cohorts.
What this means in practical terms:
Why calibration matters clinically: A well-calibrated model allows oncologists to act on the absolute value of the prediction, not just its relative position, making treatment escalation or de-escalation safer, clearer, and more evidence-based.
View a Sample Report
Explore our sample report and learn more about how predictions made by Ataraxis Breast RISK can help in recurrence risk assessment and making more personalized decisions about treatment.
Make the most informed call for your patients.
Get a clearer recurrence risk result without the wait or the gray zone
Legacy recurrence tests, such as the majority of genomic tests, can take weeks to get a result and still leave many patients in an unclear “intermediate” category. Ataraxis Breast RISK is designed to address those exact issues, and it can be used for early-stage breast cancer across:
- All molecular subtypes, regardless of ER, PR, or HER2 status
- Premenopausal women and postmenopausal women
- Regardless of cancer presence in lymph nodes
We start with the tissue your care team already collected during biopsy or surgery. Our advanced AI platform analyzes thousands of microscopic tumor features, along with basic clinical information, to estimate your personal risk of breast cancer recurrence.
I might want this test if...
I want a better sense of whether my risk of recurrence is lower or higher, and I want a prognostic tool validated across breast cancer subtypes.
I want additional insight to help decide on treatment—especially if I'm premenopausal or have lymph node involvement.
I want to reduce extra weeks of anxiety and get a clear result sooner, so I can start my treatment plan as soon as possible with my care team.
I want the most realistic recurrence risk estimate for my specific cancer type and feel confident that I am not being over-treated or under-treated.
How do we predict risk of recurrence?
Ataraxis Breast was validated in patients like you
Ataraxis Breast tests have been developed and validated using recent data of thousands of real patients from around the world. Our clinical studies show that Ataraxis Breast RISK, our test predicting risk of breast cancer recurrence, can distinguish between low and high risk in all patients with early-stage breast cancer, no matter their age, race, molecular subtype, or histology.
Choose the characteristics that best describe you. We’ll show evidence from our clinical validation study with patients like you.